Industry Insights
-
Tips For Single Cell Isolation
10/11/2022
Explore our tips for single cell isolation and how to ensure optimal results across several key application areas.
-
Bioprocessing Sees Continued Improvements In Batch Failure Reductions In 2022
7/13/2022
Bioprocessing is generally doing better than ever in terms of minimizing batch failures. In BioPlan Associates’ 19th Annual Report and Survey on Biopharmaceutical Manufacturing Production and Capacity, we discovered the leading cause of batch failures and more insights.
-
Streamlining Your Process Development Journey To GMP Manufacturing
4/5/2022
Explore key characteristics that cultivate efficient organization, alongside smooth and timely technology transfer and scale-up, from research and development to GMP manufacturing.
-
Brexit’s Impact On The Global Pharmaceutical Industry: Market Authorization & Pricing
7/12/2016
The Brexit referendum has resulted in instability and uncertainty for many aspects of British society, including the pharmaceutical industry. As we discussed in Part 1 of this two-part article, life sciences funding and the common market are at risk, and with it billions of dollars in research funding and imports/exports. In this article, we will explore the UK’s future relationship with the EU after exit, which will affect many facets of the worldwide pharmaceutical industry, from marketing authorization to global pricing trends.
-
Designing A Biomanufacturing Facility Incorporating Single-Use Technologies
12/5/2016
When building a new facility based on single-use technologies, or incorporating single-use into an existing facility, how do companies ensure they fully realize the benefits?
-
Your Capital Equipment Project Is Cancelled - Now What?
Late-stage clinical trial failures usually result in exposure with regard to capital equipment purchased to manufacture that product at a commercial scale. But what to do with this brand new, surplus equipment?
-
Best Practices In Environmental Monitoring Sampling — Transportation & Analysis
5/23/2018
The process of establishing a defendable environmental monitoring (EM) sampling plan during performance qualification can be broken into six phases. This article discusses the final two phases.
-
5 Misconceptions About Data Integrity In Pharmaceutical And Device Development & Operations
9/15/2021
Data integrity (DI) issues in pharma and medical devices have always been there, but in my experience as a consultant, these issues have increased in frequency more recently, thus moving them to the forefront. In this article, I explain five misconceptions about data integrity in our industry.
-
Cell & Gene Therapies: How Can Our Knowledge Of 2023 Inform Our Predictions For 2024?
1/8/2024
2024 promises a potential turnaround and blue skies for cell and gene therapies. Let’s explore each modality’s prospects: oligos and mRNA, cell therapies, and viral gene therapies.
-
Selectivity In SEC: It’s Much More Than Average Pore Diameter
5/22/2019
Describing the pore of a size exclusion chromatography resin with a single number such as average pore diameter is an oversimplification. The formation of pores is dependent on complex combinations of many parameters.